← Back to Screener
Nephros Inc. (NEPH)
Price$3.07
Favorite Metrics
Price vs S&P 500 (26W)-54.12%
Price vs S&P 500 (4W)-8.12%
Market Capitalization$31.40M
P/E Ratio (Annual)26.30x
All Metrics
P/CF (Annual)19.09x
Book Value / Share (Quarterly)$0.96
P/TBV (Annual)5.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.48%
Cash Flow / Share (Quarterly)$0.15
Price vs S&P 500 (YTD)-43.69%
Gross Margin (TTM)61.87%
Net Profit Margin (TTM)6.35%
EPS (TTM)$0.11
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$0.11
Revenue Growth (5Y)17.03%
EPS (Annual)$0.11
ROI (Annual)11.69%
Gross Margin (Annual)61.87%
Net Profit Margin (5Y Avg)-23.67%
Cash / Share (Quarterly)$0.51
P/E Basic Excl Extra (TTM)26.30x
Revenue Growth QoQ (YoY)22.20%
P/E Normalized (Annual)26.30x
ROA (Last FY)8.75%
Revenue Growth TTM (YoY)32.67%
EBITD / Share (TTM)$0.11
ROE (5Y Avg)-34.69%
Operating Margin (TTM)6.10%
Cash Flow / Share (Annual)$0.15
P/B Ratio3.08x
P/B Ratio (Quarterly)5.08x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.38x
Net Interest Coverage (TTM)-427.00x
ROA (TTM)9.38%
EPS Growth QoQ (YoY)-82.92%
EV / EBITDA (TTM)20.98x
EPS Incl Extra (Annual)$0.11
Current Ratio (Annual)4.06x
Quick Ratio (Quarterly)2.82x
3-Month Avg Trading Volume0.05M
52-Week Price Return56.08%
EV / Free Cash Flow (Annual)15.82x
P/E Incl Extra (TTM)26.30x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.91
P/S Ratio (Annual)1.67x
Asset Turnover (Annual)1.38x
52-Week High$6.42
Operating Margin (5Y Avg)-15.13%
EPS Excl Extra (Annual)$0.11
CapEx CAGR (5Y)40.63%
Tangible BV CAGR (5Y)-3.04%
26-Week Price Return-45.37%
Quick Ratio (Annual)2.82x
13-Week Price Return-33.11%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.06x
Enterprise Value$26.017
Revenue / Share Growth (5Y)12.69%
Asset Turnover (TTM)1.48x
Book Value / Share Growth (5Y)-5.45%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.45x
Pretax Margin (Annual)6.42%
Cash / Share (Annual)$0.51
3-Month Return Std Dev72.33%
Gross Margin (5Y Avg)56.99%
Net Income / Employee (TTM)$0
ROE (Last FY)11.70%
Net Interest Coverage (Annual)-95.00x
EPS Basic Excl Extra (Annual)$0.11
P/FCF (TTM)19.09x
Receivables Turnover (TTM)8.96x
EV / Free Cash Flow (TTM)15.82x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.11
Receivables Turnover (Annual)8.96x
ROI (TTM)12.19%
P/S Ratio (TTM)1.67x
Pretax Margin (5Y Avg)-14.82%
Revenue / Share (Annual)$1.71
Tangible BV / Share (Annual)$0.91
Forward P/E51.17x
Price vs S&P 500 (52W)20.99%
P/E Ratio (TTM)26.30x
EPS Growth TTM (YoY)1772.88%
Year-to-Date Return-39.55%
5-Day Price Return1.37%
EPS Normalized (Annual)$0.11
ROA (5Y Avg)-18.85%
Net Profit Margin (Annual)6.35%
Month-to-Date Return-1.01%
Cash Flow / Share (TTM)$-0.14
EBITD / Share (Annual)$0.11
Operating Margin (Annual)6.10%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)19.09x
ROI (5Y Avg)-34.10%
P/E Excl Extra (TTM)26.30x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.11
P/TBV (Quarterly)5.34x
P/B Ratio (Annual)5.08x
Inventory Turnover (TTM)2.45x
Pretax Margin (TTM)6.42%
Book Value / Share (Annual)$0.96
Price vs S&P 500 (13W)-35.97%
Beta1.44x
P/FCF (Annual)19.09x
Revenue / Share (TTM)$1.66
ROE (TTM)12.22%
52-Week Low$1.64
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NEPHNephros Inc. | 1.67x | 17.03% | 61.87% | 6.10% | $3.07 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Nephros Inc is a commercial-stage company developing high-performance water solutions for medical and commercial markets. The medical segment focuses on water filtration, pathogen detection, and next-generation hemodiafiltration systems for renal disease patients, while the commercial segment manufactures water filters that improve taste and reduce odor, biofilm, and equipment fouling. Revenue is primarily generated through product sales.